Key Highlights
- Third-quarter 2026 total Revenue was USD 23.1 million, against USD 23.4 million a year earlier.
- RNS System revenue was USD 22.9 million, up 1.4% from USD 22.6 million.
- Adjusted gross Margin was 84.8%, against 82.8% in the prior-year quarter.
- The company revised 2026 revenue guidance to USD 91 million to USD 92 million.
NeuroPace (NASDAQ:NPCE) reported third-quarter 2026 total revenue of USD 23.1 million, against an estimate of USD 27.13 million. The company makes the RNS System, a responsive neurostimulation device for drug-resistant epilepsy. Results discussed on the call reflect continuing operations and exclude the former SEEG distribution business, which is presented as discontinued operations.
Management said it reviewed performance across the market, sales territories and accounts after the quarter and identified several factors behind the shortfall, many of which it believes are transient. It cited local operational issues at several of its largest accounts, midyear changes to sales leadership and field roles, and the commercial effect of exiting the SEEG distribution business.
Financial Results
Chief Financial Officer Patrick Williams said RNS System revenue was USD 22.9 million, up 1.4% from USD 22.6 million. Service revenue was USD 203,000, against USD 771,000. Total revenue decreased 1.1% from USD 23.4 million. Adjusted gross margin was 84.8%, against 82.8%, which he attributed to better labor absorption, and GAAP gross margin from continuing operations was 84.3%.
Total adjusted operating expenses were USD 19.2 million, against USD 20.7 million, a decrease of approximately 7%. Adjusted sales and Marketing expense was USD 10.5 million, against USD 11.2 million, adjusted Research and Development expense was USD 5.5 million, against USD 5.8 million, and adjusted general and administrative expense was USD 3.2 million, against USD 3.7 million. GAAP operating expenses were USD 21.6 million, and total stock-based compensation was USD 2.4 million.
Adjusted income from operations was USD 0.4 million, against an adjusted operating loss of USD 1.4 million. Adjusted net loss was USD 0.9 million, against USD 2.3 million, and adjusted EBITDA was a gain of USD 0.4 million, against a loss of USD 1.3 million. GAAP net loss from continuing operations was USD 3.3 million, against USD 4.9 million.
Cash and Guidance
The company ended the quarter with USD 49.5 million in cash, cash equivalents, short-term investments and restricted cash, against USD 51.9 million at the end of the second quarter. Long-term borrowings totaled USD 59.2 million at September 30, 2026.
Management revised full-year 2026 total revenue guidance to USD 91 million to USD 92 million, from USD 99.5 million to USD 101.5 million. It said the range implies RNS System revenue of approximately USD 90 million to USD 91 million, growth of 10% to 11%, with about USD 1 million of service revenue. Based on nine-month results, the guidance implies fourth-quarter total revenue of approximately USD 23 million to USD 24 million.
The company raised its full-year adjusted gross margin outlook to 83% to 83.5%, from 82% to 83%, and lowered its full-year adjusted Operating Expense outlook to USD 85 million to USD 86 million, from USD 90 million to USD 92 million, excluding approximately USD 10 million of stock-based compensation.
Pipeline and Reimbursement
Management said it completed a Submission Issue Request meeting with the FDA in the fourth quarter for the NAUTILUS idiopathic generalized epilepsy PMA supplement, and plans to submit an amendment around year-end. It said its planning allows for a full 180-day FDA review, which would point to potential approval by midyear 2027, and that timing depends on the agency's review.
The company said CMS's final 2027 OPPS rule raises the hospital outpatient payment rate for the APC covering RNS replacement procedures by approximately 11%. For 2027, management said its current view is core RNS revenue growth of approximately 15%, accelerating toward 20% at the exit of 2027, excluding any contribution from IGE indication expansion. It also said it is pursuing a real-world evidence approach for adolescent focal epilepsy and has initiated enrollment in the AURORA retrospective observational study.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...